Try­ing to nip at As­traZeneca's heels, Lil­ly and Boehringer In­gel­heim stop a PhI­II Jar­diance study ear­ly in kid­ney dis­ease

Eli Lil­ly and Boehringer In­gel­heim re­vealed Wednes­day that a big part of their plans to com­pete with As­traZeneca’s Farx­i­ga has been val­i­dat­ed.

A Phase III tri­al eval­u­at­ing Jar­diance in chron­ic kid­ney dis­ease will be stopped ear­ly due to pos­i­tive ef­fi­ca­cy, the pair re­port­ed Wednes­day, giv­ing them a win as they seek to broad­en the drug’s use. The ear­ly halt came af­ter a rec­om­men­da­tion from the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee, and the pri­ma­ry end­point looked at both kid­ney dis­ease pro­gres­sion and car­dio­vas­cu­lar death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER